Triple Negative Breast Cancer

Triple negative breast cancer is typically treated with a combination of surgery, chemotherapy, and radiation therapy. The specific treatment plan may vary depending on the stage and characteristics of the cancer, as well as individual factors.

Surgery is often the first step in treatment and involves removing the tumor and surrounding tissue. This can be done through a lumpectomy (removal of the tumor and a small margin of healthy tissue) or a mastectomy (removal of the entire breast). Lymph node removal or biopsy may also be performed to determine if the cancer has spread.

Chemotherapy is commonly used in triple negative breast cancer because it can target rapidly dividing cells. It is usually given before surgery (neoadjuvant chemotherapy) to shrink the tumor and make it easier to remove, or after surgery (adjuvant chemotherapy) to kill any remaining cancer cells. Different chemotherapy drugs or combinations may be used based on the individual case.

Radiation therapy is often recommended after surgery to kill any remaining cancer cells in the breast or surrounding areas. It involves using high-energy beams to target the affected area.

As for the 2023 survival rate, it is not possible to provide an accurate prediction for a specific year in the future. Survival rates for triple negative breast cancer can vary depending on various factors, including the stage at diagnosis, age, overall health, and response to treatment. It is best to consult with a healthcare professional for the most up-to-date information on survival rates.

Regarding the demographic affected by triple negative breast cancer, it can occur in people of any age or ethnicity. However, it is more commonly diagnosed in younger women, particularly those under the age of 40. It is also more prevalent in African-American and Hispanic women compared to other ethnic groups. It's important to note that anyone, regardless of demographic, can be diagnosed with triple negative breast cancer.